C16 Ganglioside GM3-d9 (d18:1/16:0-d9) (ammonium salt)
(Synonyms: C16 GM3-d9, N-Hexadecanoyl-d9 (13,13,14,14,15,15,16,16,16)-Monosialoganglioside GM3) 目录号 : GC46979
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
C16 Ganglioside GM3-d9 (d18:1/16:0-d9) is intended for use as an internal standard for the quantification of C16 ganglioside GM3 by GC- or LC-MS. C16 Ganglioside GM3 (d18:1/16:0) is a monosialylated ganglioside. It has been found in human fetal frontal lobe tissue isolated in the 27th gestational week but not in human fetal anencephalic residual brain tissue isolated in the 28th gestational week.1 C16 Ganglioside GM3 (d18:1/16:0) is higher in the serum of patients with visceral fat accumulation (VFA) and patients with VFA and dyslipidemia compared to healthy lean control subjects.2 Serum levels of C16 ganglioside GM3 (d18:1/16:0) are inversely correlated with erythrocyte counts in patients with hematological diseases, including patients with lymphoid neoplasms.3 [Matreya, LLC. Catalog No. 2059]
1.Almeida, R., Mosoarca, C., Chirita, M., et al.Coupling of fully automated chip-based electrospray ionization to high-capacity ion trap mass spectrometer for ganglioside analysisAnal. Biochem.378(1)43-52(2008) 2.Veillon, L., Go, S., Matsuyama, W., et al.Identification of ganglioside GM3 molecular species in human serum associated with risk factors of metabolic syndromePLoS One10(6)e0129645(2015) 3.Nishikawa, M., Kurano, M., Nitta, T., et al.Serum GM3(d18:1-16:0) and GM3(d18:1-24:1) levels may be associated with lymphoma: An exploratory study with haematological diseasesSci. Rep.9(1)6308(2019)
| Cas No. | N/A | SDF | |
| 别名 | C16 GM3-d9, N-Hexadecanoyl-d9 (13,13,14,14,15,15,16,16,16)-Monosialoganglioside GM3 | ||
| Canonical SMILES | OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@@]2([H])[C@@H]([C@@]([C@H]([C@H](O2)CO)O)([H])O[C@]3(C([O-])=O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@@H]([C@H](O)CO)O)O3)O)O[C@H]1OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(CCCCCCCCCCCC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O.[NH4+] | ||
| 分子式 | C57H94D9N2O21.NH4 | 分子量 | 1179.5 |
| 溶解度 | Chloroform:Methanol:DI Water (2:1:0.1): soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.8478 mL | 4.2391 mL | 8.4782 mL |
| 5 mM | 0.1696 mL | 0.8478 mL | 1.6956 mL |
| 10 mM | 0.0848 mL | 0.4239 mL | 0.8478 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。